Welcome to our dedicated page for NewAmsterdam Pha SEC filings (Ticker: namsw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NewAmsterdam Pha's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NewAmsterdam Pha's regulatory disclosures and financial reporting.
James N. Topper, a director, reported purchases of NewAmsterdam Pharma Co N.V. ordinary shares on 09/08/2025. The Form 4 shows 1,260 shares acquired at a weighted average price of $24.99 (prices ranged from $24.86 to $25.00). Following the transaction, the filing reports 3,027,864 shares held indirectly by Frazier Life Sciences X, L.P. and 3,801,000 shares held indirectly by Frazier Lifesciences Sponsor LLC. The securities are held indirectly through a partnership and sponsor entities for which the reporting person is a managing member; the filing disclaims direct beneficial ownership except for pecuniary interest. The form is signed by an attorney-in-fact on behalf of Mr. Topper dated 09/10/2025.
NewAmsterdam Pharma Company N.V. insider activity is reported under Rule 144 for ordinary shares. The filer indicates an intended sale of 150,000 ordinary shares through J.P. Morgan Securities LLC with an aggregate market value of $3,780,000, and lists the approximate sale date as 09/09/2025 on NASDAQ. The shares were acquired on 11/22/2022 via an equity compensation exercise-and-sell transaction from the issuer, and payment is listed as cash. The filing also discloses two prior share sales by the same person in the past three months totaling 26,342 shares for gross proceeds of $658,999.39.
Louise Kooij, Chief Accounting Officer, filed a Form 4 reporting insider sales of NewAmsterdam Pharma Co N.V. The filing shows a sale on 09/03/2025 of 18,073 ordinary shares at a weighted average price of $25.09 per share. After the transaction the reporting person beneficially owns 15,000 shares directly. The filing includes a broker-provided weighted average price and notes that the full price range was not available at filing.
The form is a routine Section 16 disclosure signed on 09/05/2025 and does not include other transactions or derivative positions. All details reported are limited to the specific non-derivative sale and the post-transaction ownership reported by the insider.
Louise Frederika Kooij, the reporting person and Chief Accounting Officer of NewAmsterdam Pharma Company N.V. (ticker: NAMSW), executed a transaction dated 09/02/2025 reported on Form 4. The filing shows the acquisition of 18,073 ordinary shares through the exercise of an option and reports total beneficial ownership of 33,073 ordinary shares following the transaction. The option exercised had an exercise price of EUR 1.16392, was originally granted to replace an earlier award, and included a vesting schedule described in the filing. The filing also discloses that the securities were previously held indirectly through LouFre Management B.V. for the reporting person’s benefit. The Form 4 is signed by the reporting person on 09/04/2025.
NewAmsterdam Pharma Company N.V. (NAMSW) reported a Form 144 notice showing a proposed sale of 18,073 ordinary shares (nominal value EUR 0.12) with an aggregate market value of $434,655.65 to be executed through Cooperatieve Rabobank U.A. on the Nasdaq Global Market on 09/03/2025. The shares were acquired on 09/02/2025 via an option exercise from NewAmsterdam Pharma Company N.V., paid in cash. The filer also reported a prior sale of 8,269 shares on 08/25/2025 generating $205,547.82. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
NewAmsterdam Pharma Company N.V. furnished a current report to let the market know it has posted an updated corporate investor presentation on its website as of September 2, 2025. The presentation, dated the same day, is attached as Exhibit 99.1 and provides investors with the latest corporate information in slide format. The company emphasizes that this material is furnished under Regulation FD, not filed, meaning it is not subject to certain securities law liabilities and is not automatically incorporated into any of its existing or future registration statements or Exchange Act filings unless expressly stated.
Insider sale by NewAmsterdam Pharma Company N.V. officer and director. The reporting person, Louise Frederika Kooij, identified as the company's Chief Accounting Officer and a director, reported a sale of 8,269 ordinary shares on 08/25/2025 at a weighted average price of $24.86 per share. After the reported sale, the filing shows the reporting person beneficially owned 15,000 ordinary shares (direct ownership). The form notes the reported price is a weighted average from multiple transactions priced between $24.74 and $24.92, and that the filer can provide the exact share counts per trade on request.
NewAmsterdam Pharma Company N.V. (NAMSW) insider Louise Kooij filed a Form 144 reporting a proposed sale of 8,269 ordinary shares (nominal value EUR 0.12). The shares were acquired by RSU vesting on 03/26/2025 and the broker listed is Cooperatieve Rabobank U.A., Utrecht. The filing shows an approximate aggregate market value of $208,296.11 and indicates an intended sale on 08/25/2025 on the Nasdaq Global Market. The issuer's total shares outstanding are reported as 112,628,458. The filer attests there is no undisclosed material adverse information and includes the standard signature/representation language required by the form.
Insider sales totaling 100,000 ordinary shares were reported by Johannes J.P. Kastelein, Chief Scientific Officer and Director of NewAmsterdam Pharma Co N.V. (NAMSW). The Form 4 shows three dispositions: 50,000 shares sold on 08/21/2025 at a weighted average price of $24.29, 42,342 shares sold on 08/22/2025 at a weighted average price of $25.08, and 7,658 shares sold on 08/22/2025 at a weighted average price of $25.49. After these transactions, the reporting person beneficially owns 69,302 ordinary shares indirectly through Futurum B.V., over which he reports sole voting and investment control. The filing includes weighted-average price ranges for each sale batch and is signed by a power of attorney on 08/25/2025.
NewAmsterdam Pharma Company N.V. (NAMSW) Rule 144 notice: The filing reports a proposed sale of 100,000 ordinary shares (nominal value EUR 0.12) through ABN AMRO on the Nasdaq Global Market with an aggregate market value of $2,500,000.00. The filer acquired these shares by option exercise on 03/24/2025 from NewAmsterdam Pharma Company N.V., paid in cash on 03/11/2025. The filing shows prior sales by the same person of 50,000 shares on 08/21/2025 for $1,214,613.94 and 50,000 shares on 08/22/2025 for $1,257,092.68. Total shares outstanding are reported as 112,628,458. The filer certifies no undisclosed material adverse information.